C5 and paroxysmal nocturnal hemoglobinuria: Ravulizumab, approved by the US Food and Drug Administration in 2018, demonstrated non-inferiority to eculizumab in phase 3 studies of adults with PNH who were C5 inhibitor-naïve when administered IV every 8 weeks [12, 13].